Evening Talk: Aging & Genomics: Could We Live Forever One Day?
New York Genome Center
6:30 PM — 8:30 PM
CBS Medical Correspondent Dr. Max Gomez in Conversation with Aging Expert Nir Barzilai, MD
Aging & Genomics
Tuesday, October 24, 2017
6:30 PM – 7:30 PM: Panel Discussion & Audience Q&A
7:30 PM – 8:30 PM: Cocktail Reception
101 Avenue of the Americas, First Floor Auditorium
Max Gomez, PhD
Medical Correspondent, CBS, New York
Author, Cells are the New Cure: The Cutting-Edge Medical Breakthroughs That Are Transforming Our Health
Dr. Max Gomez, is a nine-time Emmy Award-winning medical correspondent with more than 30 years of broadcast experience. A highly regarded journalist, moderator and public speaker, Dr. Gomez has earned an outstanding reputation for translating complex medical topics into compelling stories. He has a special interest in genomics and aging, and is the co-author of the just released book, Cells are the New Cure: The Cutting-Edge Medical Breakthroughs That Are Transforming Our Health.
Nir Barzilai, MD
Director, Institute for Aging Research
Professor, Medicine and Genetics
Albert Einstein College of Medicine
Nir Barzilai, MD, is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, Professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics at the Albert Einstein College of Medicine.
To learn more about Dr. Barzilai’s research, visit his lab page.
To read more about Dr. Gomez’s research, please visit – Google Scholar – Max Gomez, PhD
To read more about Dr. Barzilai’s research, please visit – Google Scholar – Nir Barzilai, MD
The Evening Talks Series is sponsored by The New York Community Trust – Pyewacket Fund.
FREE AND OPEN TO THE PUBLIC
+FIVE POINTSFive Points lecture series bring leading scientists from around the world for an in-depth discussion of their work with students, researchers and clinicians from the New York Genome Center, its member institutions, and others in the medical/scientific community. While Five Points lectures are free and open to the general public, these lectures are most beneficial to scientists, clinicians and researchers who wish to accelerate their research through the use of DNA sequencing technology and bioinformatics. Five Points lectures often frame five or so key points, in a nod to the series’ name — followed by 15 minutes of Q&A, and 30 minutes of networking over hors d’oeuvres and cocktails. These afternoon events are held in the Center’s state-of-the-art ground-floor auditorium starting at 4 pm.
+EVENING TALKSThe New York Genome Center’s Evening Talks events feature distinguished experts from around the world sharing genomic insights and research. They are intended to showcase and explain high science to the non-scientific community. Speakers present the latest research findings and explain its implication for helping improve clinical care for a wide array of serious diseases. The lecture is followed by a lively question-and-answer session and a post-event reception of hors d’oeuvres and cocktails. These popular free public events are held in the Center’s state-of-the-art ground-floor auditorium starting at 6:30 pm. The Evening Talks Series is sponsored by The New York Community Trust – Pyewacket Fund.
+New York Cancer Genomics Research NetworkTo advance collaborative efforts on cancer genomics, the New York Genome Center (NYGC) hosts meetings on the first Tuesday of every month to bring together leading cancer researchers, clinicians and postdocs from the NYGC’s Institutional Founding Members and other key academic institutions. The organizers include Drs. Harold Varmus (Weill Cornell Medicine & NYGC), Marcin Imielinski (Weill Cornell Medicine & NYGC), Ross Levine (Memorial Sloan Kettering Cancer Center) and Sohail Tavazoie (The Rockefeller University).